High Tariff Proposal by Trump Alarms Swiss Financial Backers
The Swiss economy is facing a significant challenge following the imposition of a 39% export tariff on Swiss goods by US President Donald Trump. The tariff, announced on Swiss National Day, is among the highest in the world and is expected to cause market volatility in Switzerland today.
Switzerland, one of the US' biggest trade partners, exported over $60 billion worth of goods to the US last year, including pharmaceuticals, medical devices, and Nespresso coffee. The tariff is likely to increase costs for Swiss companies and reduce the competitiveness of Swiss exports in the US market.
Export-heavy sectors, especially those reliant on the US market, may face declines in revenue and profits, which typically leads to downward pressure on their stock prices. The Swiss stock market, which has trailed the STOXX 600 this year partly due to its heavy exposure to defensive versus cyclical stocks, is likely to respond negatively to the tariff.
The tariff affects some of the US' trading partners, such as Canada and Switzerland, with significantly higher duties. Pharmaceutical heavyweights Novartis AG and Roche Holding AG are facing additional pressure due to letters from Trump demanding lower drug prices.
Despite the challenges, Switzerland is actively trying to negotiate a new trade deal with the US to mitigate these effects. Holger Schmieding, chief economist at Germany's Berenberg Bank, views the tariff as a prelude to negotiations, while UBS Global Wealth Management's chief investment office stated that the current tariff rate is more of a strategy to initiate serious negotiations rather than a final rate.
Andreas Wosol, head of Amundi SA's European equity value strategies, also expects negotiations to follow the tariff announcement. Some investors see Trump's tariff announcement as a negotiating ploy, with hopes that a resolution can be reached to avoid further economic disruption for both countries.
The Swiss market could see a delayed reaction to its European peers, following the slump of the STOXX 600 by 1.9% on Friday and a worse performance by France's CAC 40, Germany's DAX, and Italy's FTSE MIB. Arthur Jurus, head of Oddo BHF investment, stated that Trump is applying unprecedented pressure on drug prices, directly targeting Swiss pharmaceutical giants.
As negotiations continue, the Swiss economy will have to navigate this challenging period, with the potential for market volatility and economic uncertainty until a resolution is reached.
The higher tariff imposed on Swiss goods by the US President, Donald Trump, has the potential to impact various sectors of the Swiss economy. This includes the finance industry, as the Swiss stock market may respond negatively due to increased costs for Swiss companies and reduced competitiveness in the US market. Additionally, the general news landscape will keep a close eye on the political dynamics surrounding the ongoing negotiations between Switzerland and the US, as a resolution in the finance sector could significantly impact the business relationships between the two countries, particularly in industries like pharmaceuticals and manufacturing.
